Given the variable expression of cGAS/STING components and high chromosomal instability in osteosarcoma, some tumour subpopulations may activate NF-κB through non-canonical STING pathways, driving malignant progression even after cytotoxic treatment. The gene discussed is NFKB1; the disease is osteosarcoma.